Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Otonomy Inc (OTIC)

$2.52 0.01 (0.59%)

14:48 EST OTIC Stock Quote Delayed 15 Minutes

Volume:

Previous Close $2.53

Market Cap 76.90M

PE Ratio -1.03

EPS -2.45

Volume (Avg. Vol.) 209,832

Day's Range 2.46 - 2.57

52-Week Range 1.50 - 3.16

Dividend & Yield N/A (N/A)

OTIC Stock Predictions, Articles, and Otonomy Inc News

From InvestorPlace
From the Web

Why Otonomy Inc (OTIC), Dycom Industries, Inc. (DY) and Mondelez International Inc (MDLZ) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer Aug 30, 2017

Dycom Industries (DY), Mondelez International (MDLZ) and Otonomy (OTIC) investors had a pretty miserable Wednesday.

Top Ranked Momentum Stocks to Buy for December 3rd

From Zacks Investment Research Dec 3, 2019

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd

What Kind Of Shareholders Own Otonomy, Inc. (NASDAQ:OTIC)?

From Simply Wall St Nov 19, 2019

If you want to know who really controls Otonomy, Inc. (NASDAQ:OTIC), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk of<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-otic/otonomy/news/what-kind-of-shareholders-own-otonomy-inc-nasdaqotic/">Read More...</a></div>

Analysts Offer Insights on Healthcare Companies: Otonomy (NASDAQ: OTIC) and Eloxx Pharmaceuticals (NASDAQ: ELOX)

From Analyst Ratings Nov 6, 2019

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Otonomy (OTIC – Research Report) and Eloxx Pharmaceuticals (ELOX – Research Report). Otonomy (OTIC) In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Otonomy, with a price target of $8.00. The company’s

Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates

From Zacks Investment Research Nov 5, 2019

Otonomy (OTIC) delivered earnings and revenue surprises of 26.67% and -59.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

From Benzinga Nov 5, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (...

Analysts Estimate Otonomy (OTIC) to Report a Decline in Earnings: What to Look Out for

From Zacks Investment Research Oct 28, 2019

Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

C

Hold